10-Q quarterly report · filed Nov 5, 2026

Sana Biotechnology, Inc. (SANA) Q3 2026 10-Q Quarterly Report

Short answer

Sana Biotechnology, Inc. (SANA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026.

Q3 2026 key financials · XBRL

Net income
$20M
+148.4% YoY · +132.1% QoQ
EPS (diluted)
$0.08
+153.3% YoY · +136.4% QoQ

Source: XBRL data from the Sana Biotechnology, Inc. (SANA) Q3 2026 10-Q on SEC EDGAR. USD.

Sana Biotechnology, Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $0, unchanged YoY, no products approved for sale
  • Net income $20.4M vs net loss $42.2M YoY, driven by $63.4M contingent consideration gain
  • R&D expense $33.9M, up $3.8M YoY, driven by SC451 and SG293 manufacturing costs
  • Cash, equivalents and securities $121.7M; nine-month operating cash use $108.9M
  • Outlook: additional capital needed within 12 months, substantial going-concern doubt, SC451 and SG293 prioritized

Risk Factors

  • New H-1B visa risk, triggered by a new one-time $100,000 fee for new petitions and proposed program reforms
  • Portfolio prioritization risk, November 2025 suspension of SC291 and SC262 development reduced pipeline breadth and increased reliance on SC451 and SG293
  • Regulatory risk, FDA boxed-warning scrutiny for CAR T malignancies could impose additional requirements on in vivo CAR T programs
  • Operational risk, limited NHP model availability has delayed preclinical studies and increased costs
  • Financial risk, substantial losses and going-concern uncertainty create dependence on additional capital for operations

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Sana Biotechnology, Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.